SBIR Phase I: Corneal Tissue Restoration with Engineered Tissue

SBIR 第一阶段：用工程组织修复角膜组织

• 批准号: 2342532
• 负责人: Amelia Zellander
• 金额: $ 27.44万
• 依托单位: BIOLATTICE, LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-12-01 至 2024-11-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2342532&HistoricalAwards=false
• 关键词: SBIR; Phase; Corneal; Tissue; Restoration

This Small Business Innovation Research (SBIR) Phase I project includes reduces the financial burden of cornea blindness and advances the medical device manufacturing industry in the US. Vision loss costs communities in lost wages and medical expenses. In 2018, the combined cost for blindness and MSVI (moderate and severe vision impairment) was $55.51 billion in North America. By providing a treatment for cornea blindness equivalent to s donor cornea, this innovation would help restore the vision of patients affected by corneal blindness, improve their ability to contribute to society, and lower the burden on their caretakers. In addition, by contributing to the general process of tissue engineering, the engineered cornea will help foster research in the field of alternatives to donor tissues, which will contribute to the well-being of individuals in society as a whole. The development of engineered cornea would also help advance the position of the US in the cornea replacement material field and more generally in the engineered tissue research field and could result in growth opportunities in the medical device manufacturing industry, therefore increasing US competitiveness.This Small Business Innovation Research (SBIR) Phase I project creates a novel acellular polymer membrane for use as a cornea substitute. The artificial cornea will differentiate itself from other artificial cornea options by offering a true alternative to donor cornea for full thickness cornea replacement (also known as penetrating keratoplasty). The artificial cornea will consist of a crosslinked polymer membrane that will provide biocompatibility with ocular tissues and suturability similar to a donor cornea. In addition, specific surface modifications will be added to the membrane to maintain its optical clarity, by preventing the adhesion of environmental and biological contaminants. These modifications will enable secure integration into the patient’s eye. The new materials will be aesthetically equivalent to existing donor cornea. By contrast to current artificial cornea options, the artificial cornea aims to provide a true replacement to donor cornea that can be used as a standard of care treatment for full thickness cornea replacement, without the risks generally associated with donor cornea tissue and without the need for refrigeration or complicated transport logistics.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）I阶段项目包括减少角膜失明的财务燃烧，并促进美国医疗设备制造业的发展。视力损失使社区损失工资和医疗费用。 2018年，北美的失明和MSVI（中度和重度视力障碍）的总成本为555.1亿美元。通过提供相当于S供体角膜的角膜失明的治疗方法，这项创新将有助于恢复受角膜失明影响的患者的愿景，提高他们为社会做出贡献的能力，并降低对看护者的烧伤。此外，通过为组织工程的一般过程做出贡献，工程角膜将有助于促进供体组织替代领域的研究，这将有助于整个社会中个人的福祉。工程角膜的发展还将有助于提高美国在角膜替代材料领域的位置，更普遍地在工程组织研究领域中，并可能导致医疗设备制造业的增长机会，从而提高美国的竞争力。这一小型企业创新研究（SBIR）I期项目创造了一种新型的acellular聚合物象征，以供角膜型替代品。人造角膜将通过提供供体角膜的真正替代品来与其他人造角膜选择区分开来，以实现全厚的角膜替代品（也称为穿透性角膜生成形术）。人造角膜将由交联的聚合物膜组成，该聚合物膜将提供与眼组织的生物相容性和类似于供体角膜的辅助性。此外，通过防止环境和生物污染物的粘合剂，将在膜中添加特定的表面修饰以保持其光学清晰度。这些修改将使安全整合到患者的眼中。新材料在美学上等同于现有的捐赠者角膜。与当前的人造角膜选择相反，人造角膜旨在为供体角膜提供真正的替换，可以用作全厚的角膜更换的护理水平治疗，而无需通常与捐赠者角膜组织相关的风险，而无需进行冷藏或复杂的运输物流，而不需要进行复杂的运输奖。 标准。